AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02262026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03775265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02262026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02234713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Study NCT02234713 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video Attention Control
Study NCT01541904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-118 Ophthalmic Solution 0.015%
Description: PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
Study NCT01541904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-118 Ophthalmic Solution 0.015 %
Description: PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
Study NCT01541904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-118 Ophthalmic Solution 0.020 %
Description: PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
Study NCT01541904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-118 Ophthalmic Solution 0.020 %
Description: PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
Study NCT01541904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Placebo Ophthalmic Solution applied qd during 21 days
Study NCT00603096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare
Description: The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
Study NCT00603096 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare
Description: The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
Study NCT04181008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Amiloride Nasal Spray
Study NCT03775265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Given IV
Study NCT03305588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unframed Virtual Cone
Description: The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
Study NCT03302884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological sampling
Description: Tumor and blood samples
Study NCT03316287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid
Description: Smart hearing aid to allow collection of real time hearing aid usage data
Study NCT03316287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile phone
Description: Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests
Study NCT03316287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor
Description: Wearable biosensor for the collection of physiological data
Study NCT02387333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion
Description: After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.~A preferred rectal muscle splitting approach is preferred for IC exteriorization.~Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.~Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.~The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.~The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.~A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.~The stoma is then everted and fixed to the skin.
Study NCT02532972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Med-el MAESTRO Cochlear Implant with Flex 28 electrode array
Description: Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
Study NCT02387333 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Ileal conduit urinary diversion
Description: In this group, no mesh will be applied with ileal conduit urinary diversion
Study NCT02379988 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Verify radiation dose to heart and lung
Description: This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
Study NCT01213459 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical samples
Description: Human papillomavirus detection and typing in cervical samples.
Study NCT01213459 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Questionnaire completion
Study NCT03791281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASIS
Study NCT03791281 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Study NCT00520702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intensity Modulated Radiation Therapy
Description: 66 Gy in 33 Daily Fractions at 2 Gy per fraction.
Study NCT00520702 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: 66 Gy in 33 Daily Fractions at 2 Gy per fraction.
Study NCT00431444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene
Study NCT00431444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid
Study NCT00431444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral pills
Study NCT00431444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo intravenous (i.v.) infusion
Study NCT03213938 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol.~Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks).
Study NCT03213938 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35.~Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks).
Study NCT01794078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline 400 mg
Description: Xanthine derivative
Study NCT03983759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab maintenance
Description: the patients with CR, PR or SD after the chemotherapy plus R-CIK will receive sintilimab maintenance therapy. The dose of sintilimab is fixed at 200mg every three weeks.
Study NCT01794078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan 5 mg
Description: Endothelin receptor antagonist
Study NCT02029469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ascension HRA device
Description: Patients who are treated with the Ascension® HRA for resurfacing of humeral head.
Study NCT01794078 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04536116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality headset
Description: MRI simulation with a Virtual Reality headset
Study NCT02438098 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rivaroxaban 10 mg
Description: Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
Study NCT00717691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metatarsophalangeal Extension Dynasplint System
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
Study NCT01990508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted beverage education and financial incentives
Study NCT01990508 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Traffic-light labeling of all beverages in store
Description: All beverages in the supermarket will be labeled as red, yellow, or green
Study NCT01990508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traffic-light labeling of all beverages in store
Description: All beverages in the supermarket will be labeled as red, yellow, or green
Study NCT00635869 — intervention group
Intervention type: BEHAVIORAL
Intervention: ARCC standard information
Description: EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
Study NCT00635869 — intervention group
Intervention type: BEHAVIORAL
Intervention: ARCC enhanced
Description: same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
Study NCT00717691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
Study NCT00717691 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Standard of Care
Description: The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
Study NCT01596400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: granisetron transdermal system
Description: patch
Study NCT01596400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron IV
Description: IV
Study NCT00635869 — intervention group
Intervention type: BEHAVIORAL
Intervention: Placebo
Description: didactic education sessions on physical assessment
Study NCT04155905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fistulotomy and marsupialization of wound edges
Description: after defining the fistulous track it was laid open (marsupialization) was done together with marsupialization of the wound edge with vicryl 3\\0 sutures
Study NCT04155905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fistulotomy
Description: after defining the fistulous track it was laid open (marsupialization)
Study NCT01339819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Patients assigned to this group will receive Dabigatran
Study NCT01339819 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenprocoumon
Description: Patients assigned to this group will receive Phenprocoumon
Study NCT00918775 — intervention group
Intervention type: OTHER
Intervention: Follow-Up Care
Description: Undergo follow-up
Study NCT00918775 — intervention group
Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01642498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ROX COUPLER
Description: The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
Study NCT02558036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C-Mac D-Blade Videolaryngoscope
Description: Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
Study NCT03568175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion, 2.0 mg/kg/week
Study NCT02877641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Given PO
Study NCT02877641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02877641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02877641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Given PO
Study NCT02877641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamin
Description: Given PO
Study NCT02558036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: C-Mac D-Blade Videolaryngoscope
Description: Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
Study NCT02877641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT02877641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02877641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03709706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lete-cel
Description: lete-cel will be administered to eligible participants.
Study NCT02558036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: King Vision Videolaryngoscope
Description: Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
Study NCT02558036 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: King Vision Videolaryngoscope
Description: Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
Study NCT03400865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ/CQ and CAB combined treatment
Description: Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.
Study NCT03181217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water 0
Description: 300 ml tap water at 0 ºC
Study NCT03181217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: water 22
Description: 300 ml tap water at 22 ºC
Study NCT03181217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose 0
Description: 300 ml tap water at 0 ºC with 75 grams of glucose added
Study NCT03181217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose 22
Description: 300 ml tap water at 22 ºC with 75 grams of glucose added
Study NCT05177978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine
Description: Phosphatidylserine containing supplement (2 x chewable gummies/day; Total daily dose of 100 mg elemental phosphatidylserine)
Study NCT03709706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered to eligible participants.
Study NCT04048850 — intervention group
Intervention type: DRUG
Intervention: Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER]
Description: Daily medication
Study NCT02690064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acute Antioxidant
Description: Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
Study NCT02690064 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chronic Antioxidant
Description: Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
Study NCT02690064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
Study NCT04429542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCA101
Description: EGFR/TGFβ fusion monoclonal antibody
Study NCT05177978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator (2 x chewable gummies/day, matched to shape and color without active ingredient)
Study NCT02904330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K1-70 intramuscular or K1-70 intravenous
Description: Each subject will receive one dose of K1-70 by IM injection or one dose of K1-70 by IV infusion on the morning of Day 1.
Study NCT02312661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
Study NCT04429542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: anti-PD-1
Study NCT02312661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
Study NCT02312661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
Study NCT02268604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB 722 CL
Study NCT02268604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03624894 — intervention group
Intervention type: OTHER
Intervention: impression
Description: common polyvinylsiloxane oral impression
Study NCT01448811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AEP monitor
Description: In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI>40, titrate up propofol dosage, AAI\<25, titrated down propofol dosage.
Study NCT01448811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ramsay Sedation Scale
Description: During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
Study NCT01115634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibroblast
Description: 20 million cell in three injection
Study NCT01115634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fibroblast and gel
Description: 20 million cell in three injection plus filler
Study NCT00954434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: red wine
Description: intake of red wine on a daily basis
Study NCT02589184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypergravity
Description: the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing
Study NCT02589184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isometric load
Description: at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load
Study NCT02589184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: normal gravity
Description: the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity
Study NCT02589184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal gravity
Description: the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity